WUGEN
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and T-cell malignancies.
WUGEN
Social Links:
Industry:
Biotechnology Therapeutics
Founded:
2018-01-01
Address:
St Louis, Missouri, United States
Country:
United States
Website Url:
http://www.wugen.com
Total Employee:
51+
Status:
Active
Total Funding:
172 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Acrivon Therapeutics
Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Investors List
Intermediate Capital Group
Intermediate Capital Group investment in Series B - Wugen
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Wugen
Lightchain
Lightchain investment in Series B - Wugen
Aisling Capital
Aisling Capital investment in Series B - Wugen
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Wugen
Alpha Wave Global
Alpha Wave Global investment in Series B - Wugen
LYZZ Capital
LYZZ Capital investment in Series B - Wugen
Abingworth
Abingworth investment in Series B - Wugen
Tybourne Capital Management
Tybourne Capital Management investment in Series B - Wugen
Velosity Capital
Velosity Capital investment in Series B - Wugen
Official Site Inspections
http://www.wugen.com Semrush global rank: 9.54 M Semrush visits lastest month: 141
- Host name: 82.29.193.177
- IP address: 82.29.193.177
- Location: Manchester United Kingdom
- Latitude: 53.4142
- Longitude: -2.228
- Timezone: Europe/London
- Postal: M20
More informations about "Wugen"
Wugen - Crunchbase Company Profile & Funding
Wugen is developing off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in …See details»
About us - Wugen
About Us OPTIMIZED BY EVOLUTION Wugen is developing off-the-shelf cellular therapies for cancer Our cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer …See details»
Wugen - LinkedIn
Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.See details»
Board of Directors - Wugen
Board of Directors Peter Kiener Chair Dr. Kiener is currently a Venture Partner at ICG Life Sciences. Peter is an industry veteran with extensive experience in both biologics and …See details»
Wugen 2025 Company Profile: Valuation, Funding
Wugen General Information Description. Developer of a novel CAR-T therapy intended for treating T-cell malignancies. The company is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell …See details»
WUGEN Company Profile | Management and Employees List
Founded in 2018, Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T-cell …See details»
Wugen, Inc. Company Profile | Saint Louis, MO - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Wugen, Inc. of Saint Louis, MO. Get the latest business insights from Dun & Bradstreet.See details»
Wugen Company Profile - Office Locations, Competitors, Revenue …
Wugen Summary. Company Summary. Overview. Wugen is a biotechnology company developing cancer treatment therapies. It focuses on creating immuno-oncology therapies to treat solid …See details»
Wugen CEO and Key Executive Team | Craft.co
Wugen's President & Chief Executive Officer is Kumar Srinivasan. Other executives include Matthew Cooper, Co-Founder & Chief Scientific Officer; Ayman Kabakibi, Chief Operating …See details»
Wugen | Company Overview & News - Forbes
Wugen Company Stats. As of March 2023. Industry Biotechnology & Agriculture Founded 2018 Headquarters St Louis, Michigan Country/Territory United States President & CEO Dan Kemp. …See details»
WUGEN - Overview, News & Similar companies | ZoomInfo.com
Who is WUGEN. Founded in 2018, Wugen Inc., is a biotechnology company developing a novel CAR-T therapy platform including an "off-the-shelf" fratricide-resistant CAR-T cell therapy for T …See details»
Wugen - Products, Competitors, Financials, Employees, …
Wugen leverages its proprietary Moneta platform and expertise in genomic engineering to create these allogeneic cellular products. It was founded in 2018 and is based in Saint Louis, …See details»
Cellipont Bioservices and Wugen Sign Agreement for the Clinical ...
Mar 14, 2024 THE WOODLANDS, Texas and ST. LOUIS, March 14, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing …See details»
Cellipont Bioservices and Wugen Sign Agreement for the Clinical ...
Mar 14, 2024 The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization …See details»
Wugen, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
“Wugen’s progress in advancing WU-CART-007 also includes a robust, scalable and efficient commercial manufacturing process, developed with our partners to create a CD7-targeted …See details»
BioGenerator Company Wugen Raises $172 Million to Advance
About Wugen Wugen, Inc., is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) cell therapies to treat a broad range of hematological and …See details»
Cellipont Bioservices and Wugen Sign Agreement for the Clinical ...
Mar 14, 2024 The Woodlands, TX, and St. Louis, MO, March 14, 2024/ Cision / – Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization …See details»
ICG Life Sciences makes investment in Wugen Inc. - ICG
Jul 15, 2021 Wugen’s memory NK cell platform, with enhanced tumor-killing functionality and in vivo persistence is designed to overcome the limitations of conventional NK cell therapies. In …See details»
Wugen Announces Dosing of First Patients in Pivotal Trial of Off …
Mar 20, 2025 About Wugen Wugen, Inc. is a clinical-stage U.S. biotechnology company developing the next generation of off-the-shelf CAR-T and memory natural killer (NK) cell …See details»
BioGenerator-backed Wugen, which has raised $200M+ in VC …
Wugen plans to enroll up to 44 patients as part of its multi-site clinical trial. One of Wugen’s sites for the clinical trial is Washington University School of Medicine. Wugen President and CEO …See details»